Sign In
Buy GLYC
$15.71
+0 (+0%)
At Close: Oct 01, 2025
23 Biotechnology Stocks Moving In Monday's After-Market Session
12:00am, Monday, 27'th Jan 2020Arbutus Biopharma (NASDAQ:ABUS) and GlycoMimetics (NASDAQ:GLYC) Head-To-Head Contrast
06:46am, Friday, 17'th Jan 2020
Arbutus Biopharma (NASDAQ:ABUS) and GlycoMimetics (NASDAQ:GLYC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of th
GlycoMimetics (NASDAQ:GLYC) Cut to Sell at Zacks Investment Research
06:14am, Friday, 17'th Jan 2020
GlycoMimetics (NASDAQ:GLYC) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zack
Week In Review: 4 China Biopharmas Announce $100+ Million Deals In First Week Of 2020
04:22pm, Sunday, 12'th Jan 2020
Apollomics of Hangzhou announced a $189 million agreement to develop two GlycoMimetics novel E-selectin-based immunotherapies in China for leukemia. Nanjing's A
GlycoMimetics (NASDAQ:GLYC) Downgraded to Hold at Zacks Investment Research
12:32pm, Sunday, 12'th Jan 2020
Zacks Investment Research lowered shares of GlycoMimetics (NASDAQ:GLYC) from a buy rating to a hold rating in a research note released on Wednesday morning, Zacks.com reports. According to Zacks, “G
Week In Review: Four China Biopharmas Announce $100+ Million Deals In First Week Of 2020
09:11pm, Saturday, 11'th Jan 2020
Apollomics of Hangzhou announced a $189 million agreement to develop two GlycoMimetics novel E-selectin-based immunotherapies in China for leukemia. Apollomics will be responsible for developing uprol
Week In Review: Four China Biopharmas Announce $100+ Million Deals In First Week Of 2020
12:00am, Saturday, 11'th Jan 2020Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug.
10:14pm, Monday, 06'th Jan 2020
Just four days after Intrexon Corp. (NASDAQ: XON) made public plans to rebrand as Precigen, its subsidiary by the same name has secured a coveted regulatory designation for its blood cancer treatment.
Md. biotech outlines path for blood cancer drug, including in China
08:02pm, Monday, 06'th Jan 2020
The local company has given a California biopharma exclusive rights to develop and commercialize its drug for a serious form of blood cancer in China.
ROCKVILLE, Md. & FOSTER CITY, Calif. & HANGZHOU, China--(BUSINESS WIRE)--GlycoMimetics, Inc. (NASDAQ: GLYC), a leader in the field of applied glycotechnology for cancer, and Apollomics, Inc., an innov
Privacy and data in 2019: We deserve better than surveillance capitalism
05:00am, Thursday, 02'nd Jan 2020
Karlin Lillington: Tech companies now face greater legal and regulatory opposition
Hedge Funds Dropped The Ball On GlycoMimetics, Inc. (GLYC)
04:09pm, Thursday, 19'th Dec 2019
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do n
